Viking Therapeutics Is Having a Year to Remember: Time to Buy?
Viking Therapeutics Inc. NASDAQ: VKTX, a clinical-stage biotechnology company with a market cap approaching $7 billion, is turning heads in 2024. Year to date, the stock has surged an impressive 238%, and its rise over the past 12 months has been even more dramatic, with shares climbing 326%.
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Viking Therapeutics, Inc. (VKTX) closed at $67.10 in the latest trading session, marking a +0.55% move from the prior day.
Why Investors Plowed Into Viking Therapeutics Stock Today
Many investors and prognosticators think one investigational drug in particular has vast potential. If ultimately approved, VK2735 would surely be competitive in a highly popular segment.
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Why Viking Therapeutics Stock Rocked the Market Today
An analyst initiated coverage of the biotech. He's optimistic about its future, to put it mildly.
Why Analysts Predict a November Surge for Viking Therapeutics Stock
Viking Therapeutics (VKTX) shares rose more than 10% Wednesday after J.P. Morgan analysts initiated coverage of the company with an "overweight" rating and a price target of $80 per share, calling the company's oral weight-loss drug currently in clinical trials "underappreciated.
Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan
JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics Inc VKTX with an Overweight rating and a December 2025 price target of $80, which implies a potential 45% upside from its current price of $54.65.
Viking Therapeutics, Inc. (VKTX) Laps the Stock Market: Here's Why
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $54.78, signifying a +1.2% move from its prior day's close.
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead?
Viking Therapeutics is developing a weight management treatment candidate that is similar to Eli Lilly's Zepbound. Analysts' estimates for Viking Therapeutics point to huge gains for the stock over the next 12 months.
Prediction: This Biotech Stock Will Outperform Nvidia in the Second Half of the Year
This stock already beat Nvidia's performance in the first half. This player operates in a market that could reach $100 billion by the end of the decade.
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Viking Therapeutics, Inc. (VKTX) reachead $58.10 at the closing of the latest trading day, reflecting a -0.5% change compared to its last close.
Viking Surges 342% in the Past Year: How Should You Play the Stock?
VKTX stock continues to generate phenomenal returns, driven by encouraging development of its obesity and NASH drugs, which are nearing late-stage development.
